Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
ID: 348234Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348234

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-193.html
Timeline
    Description

    The National Institutes of Health (NIH), through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), has announced a funding opportunity titled "Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)." This initiative aims to facilitate the development of non-hormonal contraceptives and reproductive health products by providing access to essential preclinical services, including protein generation, high throughput screening, and drug metabolism studies, rather than direct funding. The program is particularly significant in addressing the urgent need for effective contraceptive methods and advancing innovative research in reproductive health. Interested applicants, including various educational and community organizations, must adhere to specific guidelines and submit their applications by April 3, 2026, with an initial deadline of October 3, 2023. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-193.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-193-Full-Announcement.html
    PAR-23-193.html
    The Department of Health and Human Services, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), has released a funding opportunity aimed at facilitating the development of non-hormonal contraceptives and reproductive health products via its Chemical Screening and Optimization Facility (CSOF). This initiative, designated as the X01 Resource Access Award, does not provide direct funding but offers access to various preclinical services essential for research, including protein generation, high throughput screening, and drug metabolism studies. Key details include application deadlines of October 3, 2023, and repeated cycles until 2026. The goal is to enable the advancement of projects that show promise in reproductive health, thereby addressing the urgent need for effective contraceptive methods. Applicants are encouraged to reach out to NICHD staff for guidance prior to submission. The application process requires adherence to specific guidelines, with an emphasis on target validation and the expected impacts on product development. Researchers must demonstrate compliance with NIH policy and clear project advancement plans. Overall, this funding opportunity aims to push forward innovative research while ensuring strong support for public health initiatives related to reproductive health.
    Similar Opportunities
    Biological Testing Facility (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Biological Testing Facility (X01 Clinical Trial Not Allowed)" aimed at advancing contraceptive development programs through the provision of specialized services. This funding opportunity announcement (FOA) is designed to support innovative and validated methods that are essential for future clinical development, allowing applicants who may not currently hold NIH funding to apply, although priority may be given to those with existing NIH support. The grant is categorized under Income Security and Social Services, with no cost-sharing or matching requirements, and is open to a diverse range of eligible applicants, including various educational institutions and organizations. Interested parties should note that the application deadline is May 2, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-128.html.
    Biological Testing Facility (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Biological Testing Facility (X01 Clinical Trial Not Allowed)" aimed at supporting research in the development of non-hormonal contraceptive methods. This grant allows investigators to access the Biological Testing Facility (BTF) for preclinical studies and Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies, with a focus on advancing contraceptive development to address unintended pregnancies in the U.S. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with applications due by May 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-192.html.
    Contraceptive Development Research Centers (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Contraceptive Development Research Centers (P50 Clinical Trial Optional)" aimed at advancing the development of new and improved contraceptive methods for both men and women. This initiative seeks to establish multidisciplinary Contraceptive Development Research Centers that will conduct laboratory and clinical research, including translational studies to enhance the likelihood of clinical success. The program is particularly focused on late-stage preclinical or clinical development of contraceptive products, encouraging proposals that explore innovative options such as non-steroidal contraceptives and novel delivery mechanisms. Up to $6 million in funding is available for fiscal year 2026, with a project period of up to four years. Interested applicants must submit their proposals by November 13, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    NICHD Small Research Grant Program (R03 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03 Clinical Trial Required) to support clinical trials aligned with the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This program aims to fund small-scale research projects, including pilot studies and methodological development, with a maximum budget of $50,000 per year for up to two years. The funding is crucial for advancing knowledge in human development fields, particularly in childhood development and rehabilitation medicine. Interested applicants must adhere to specific guidelines and register with Grants.gov and eRA Commons, with the application window opening on January 16, 2025, and closing on January 8, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NICHD Small Research Grant Program (R03 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03 Clinical Trial Required) to support clinical trials that align with the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This grant program is designed to fund small research projects with a maximum budget of $50,000 in direct costs per year, for a duration of up to two years, focusing on areas such as human development, childhood development, and rehabilitation medicine. Eligible applicants include a diverse range of organizations, including higher education institutions, nonprofits, for-profits, and tribal governments, with all applications required to propose clinical trials and adhere to NIH submission guidelines. Interested parties should note that the application deadline is January 7, 2025, and can reach out to the NIH OER Webmaster at grantsinfo@nih.gov for further inquiries. More information can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PA-21-221.html.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)" aimed at promoting research and development of novel screening methods and therapeutic interventions for conditions identified through newborn screening. This initiative encourages innovative projects that generate preliminary data on both existing and potentially fatal genetic disorders, emphasizing the importance of early detection and intervention. The program is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and governmental bodies, with a total funding ceiling of $275,000 over two years. Interested applicants should note that the submission deadlines begin on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03), which supports small clinical trials focused on basic experimental studies involving human participants. This funding opportunity aims to enhance understanding of fundamental phenomena without immediate application towards products or processes, aligning with the NICHD's mission in human development, behavior, and health. Grants are available for up to $50,000 in direct costs per year, with a maximum project duration of two years, and applications must be submitted by January 7, 2025. Interested applicants can find more information and application details at the NIH website or contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance.
    NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03), which provides funding for basic experimental studies involving human participants that align with the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This grant supports clinical trials aimed at understanding fundamental aspects of phenomena without immediate application to processes or products, encouraging innovative research in areas such as contraception and childhood development. Eligible applicants include a wide range of entities, such as higher education institutions, nonprofits, and tribal organizations, with a funding ceiling of $50,000 available over a maximum of two years. Interested parties should note that the application period opens on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at advancing research in novel screening methods and therapeutic interventions for genetic conditions identified through newborn screening. This initiative encourages the development of innovative screening assays, the use of artificial intelligence, and the exploration of socio-economic implications related to newborn screening, with a focus on conditions that may benefit from early detection and treatment. The grant supports long-term research projects (R01) and is open to a diverse range of applicants, including higher education institutions and community-based organizations, with applications accepted until November 16, 2027. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-265.html.
    Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators" through the National Cancer Institute (NCI). This initiative aims to support research focused on the identification and development of small molecules that can elucidate cancer biology and contribute to therapeutic advancements. The funding is intended for various eligible applicants, including educational institutions and non-profit organizations, with a flexible budget and a project duration of up to three years. Key deadlines include an application submission window starting January 5, 2025, and a closing date of September 7, 2026. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-153.html.